UroGen Pharma Ltd. (NASDAQ:URGN – Get Free Report) has received a consensus rating of “Buy” from the six brokerages that are currently covering the company, Marketbeat.com reports. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $38.20.
A number of brokerages have commented on URGN. D. Boral Capital restated a “buy” rating and issued a $25.00 target price on shares of UroGen Pharma in a research note on Monday, March 10th. HC Wainwright cut their price target on UroGen Pharma from $64.00 to $55.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. Finally, LADENBURG THALM/SH SH began coverage on UroGen Pharma in a report on Wednesday, February 19th. They set a “buy” rating and a $31.00 price target on the stock.
View Our Latest Research Report on UroGen Pharma
Insider Buying and Selling
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of URGN. KLP Kapitalforvaltning AS purchased a new position in UroGen Pharma during the 4th quarter worth approximately $59,000. Lazard Asset Management LLC purchased a new position in UroGen Pharma during the 4th quarter worth approximately $67,000. Aquatic Capital Management LLC purchased a new position in UroGen Pharma during the 4th quarter worth approximately $101,000. BNP Paribas Financial Markets grew its holdings in shares of UroGen Pharma by 221.8% during the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after acquiring an additional 5,890 shares in the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of UroGen Pharma during the 4th quarter valued at $126,000. Institutional investors own 91.29% of the company’s stock.
UroGen Pharma Stock Performance
Shares of URGN stock opened at $11.07 on Friday. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77. The business has a 50 day moving average of $10.45 and a two-hundred day moving average of $11.65. UroGen Pharma has a 52 week low of $9.03 and a 52 week high of $20.70. The company has a market cap of $259.64 million, a P/E ratio of -3.51 and a beta of 1.12.
UroGen Pharma (NASDAQ:URGN – Get Free Report) last issued its earnings results on Monday, March 10th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). The business had revenue of $24.57 million during the quarter, compared to the consensus estimate of $25.25 million. As a group, analysts anticipate that UroGen Pharma will post -3.12 EPS for the current year.
About UroGen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
See Also
- Five stocks we like better than UroGen Pharma
- Canadian Penny Stocks: Can They Make You Rich?
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- Stock Market Upgrades: What Are They?
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.